IMUNON's Ovarian Cancer Drug IMNN-001 Extends Survival by Up to 24.2 Months in Updated Phase 2 Data
IMNN sits 19% above its 52-week low of $2.835.
Summary
Imunon announced updated final Phase 2 data for IMNN-001 in newly diagnosed advanced ovarian cancer, showing a median overall survival (OS) increase of 14.7 months (45.1 vs. 30.4 months) compared to standard of care. Critically, patients treated with IMNN-001 and PARP inhibitors achieved an even more significant median OS increase of 24.2 months (65.6 vs. 41.4 months). This highly positive clinical update follows recent SEC filings regarding an expanded ATM offering, providing strong justification for the capital raise. The substantial and continuous improvement in overall survival, coupled with a favorable safety profile, significantly de-risks the lead drug candidate and enhances its commercial potential in a disease with limited recent advancements. The company also noted that enrollment for its pivotal Phase 3 OVATION 3 trial is ahead of schedule, with planned interim analyses that could accelerate a Biologics License Application (BLA) submission.
At the time of this announcement, IMNN was trading at $3.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $2.84 to $41.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.